Northwell Health Genomics Alliance Data Inititatives

One of the goals of the Northwell Health Genomics Alliance is to develop a shared database consisting of annotated genomic data with detailed clinical information, which will help build the evidence base for the medical necessity of genomic and genetic testing in clinical practice. To this end, when orders for OnkoSight tumor sequencing are ordered online through CareEvolve or the EMR, clinicians are prompted to answer a set of questions about the patient case that will feed into the genomic database. The pre-order questions for these tests are demonstrated below.

Clinical Information
Initial Diagnosis or Relapse:
Age at Diagnosis:

Pathology-directed questions

Anatomic Location of Primary Lesion:
Anatomic Location of Biopsy Being Tested:
Known Germline Mutation:
Histology:
Tumor Size:
Tumor Burden:

Oncology-directed questions

Type of Cancer Legion:
Reason for Molecular Testing: Other:
TNM Staging Clinical:
ECOG Performance Status:
Prior Treatment:
Number of Prior Treatment:
Refractory to Current Standard Therapy:
Relapsed
(recurrance greater than 6 months after current standard treatment):
Current Treatment:
Test Specific Information
B821-0 OnkoSight Solid Tumor
Clinical Information
Initial Diagnosis or Relapse:
Age at Diagnosis:

Pathology-directed questions

Anatomic Location of Primary Lesion:
Anatomic Location of Biopsy Being Tested:
Diagnosis Under Consideration:
Other:
Diagnosis (if known):
Known Germline Mutation:

Oncology-directed questions

Type of Cancer Legion:
Reason for Molecular Testing: Other:
TNM Staging Clinical:
ECOG Performance Status:
Prior Treatment:
Number of Prior Treatment:
Refractory to Current Standard Therapy:
Relapsed
(recurrance greater than 6 months after current standard treatment):
Current Treatment:
Test Specific Information
B823-6 OnkoSight Myeloid Seq